Moreover, peptide analogues that are unimolecular co-agonists of both GLP-1R and GCGR are currently in clinical development for the treatment of T2D, obesity and non-alcoholic steatohepatitis (NASH)2,3,5–7. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.